CAMKs Support Development of Acute Myeloid Leukemia

Overview

Journal J Hematol Oncol

Publisher Biomed Central

Specialties Hematology
Oncology

Date 2018 Feb 28

PMID 29482582

Citations 19

Authors

Xunlei Kang

Changhao Cui

Chen Wang

Guojin Wu

Heyu Chen

Zhigang Lu

Xiaoli Chen

Li Wang

Jie Huang

Huimin Geng

Meng Zhao

Zhengshan Chen

Markus Muschen

Huan-You Wang

Cheng Cheng Zhang

Affiliations

Soon will be listed here.

Abstract

Background: We recently identified the human leukocyte immunoglobulin-like receptor B2 (LILRB2) and its mouse ortholog-paired Ig-like receptor (PirB) as receptors for several angiopoietin-like proteins (Angptls). We also demonstrated that PirB is important for the development of acute myeloid leukemia (AML), but exactly how an inhibitory receptor such as PirB can support cancer development is intriguing.

Results: Here, we showed that the activation of Ca (2+)/calmodulin-dependent protein kinases (CAMKs) is coupled with PirB signaling in AML cells. High expression of CAMKs is associated with a poor overall survival probability in patients with AML. Knockdown of CAMKI or CAMKIV decreased human acute leukemia development in vitro and in vivo. Mouse AML cells that are defective in PirB signaling had decreased activation of CAMKs, and the forced expression of CAMK partially rescued the PirB-defective phenotype in the MLL-AF9 AML mouse model. The inhibition of CAMK kinase activity or deletion of CAMKIV significantly slowed AML development and decreased the AML stem cell activity. We also found that CAMKIV acts through the phosphorylation of one of its well-known target (CREB) in AML cells.

Conclusion: CAMKs are essential for the growth of human and mouse AML. The inhibition of CAMK signaling may become an effective strategy for treating leukemia.

Citing Articles

Sintilimab plus decitabine for higher-risk treatment-naïve myelodysplastic syndromes: efficacy, safety, and biomarker analysis of a phase II, single-arm trial.

Wang J, Li S, Jiang H, Chang Y, Zhao X, Jia J J Immunother Cancer. 2024; 12(11).

PMID: 39577869 PMC: 11590843. DOI: 10.1136/jitc-2024-010355.

Inhibiting AGTR1 reduces AML burden and protects the heart from cardiotoxicity in mouse models.

Pan Y, Wang C, Zhou W, Shi Y, Meng X, Muhammad Y Sci Transl Med. 2024; 16(752):eadl5931.

PMID: 38896605 PMC: 11250918. DOI: 10.1126/scitranslmed.adl5931.

Angiopoietin-like protein 2 inhibits thrombus formation.

Zhang T, Zhang M, Guo L, Liu D, Zhang K, Bi C Mol Cell Biochem. 2024; 480(2):1169-1181.

PMID: 38880861 PMC: 11835982. DOI: 10.1007/s11010-024-05034-9.

LILRB2 promotes immune escape in breast cancer cells via enhanced HLA-A degradation.

Jiang Z, Huang Q, Chang Y, Qiu Y, Cheng H, Yang M Cell Oncol (Dordr). 2024; 47(5):1679-1696.

PMID: 38656573 DOI: 10.1007/s13402-024-00947-5.

Leukocyte immunoglobulin-like receptor B2 overexpression as a promising therapeutic target and noninvasive screening biomarker for colorectal cancer.

Wang Q, Zhou L, Qin G, Tan C, Zhou Y, Yao S World J Gastroenterol. 2023; 29(37):5313-5326.

PMID: 37899785 PMC: 10600801. DOI: 10.3748/wjg.v29.i37.5313.

References

Si J, Collins S . Activated Ca2+/calmodulin-dependent protein kinase IIgamma is a critical regulator of myeloid leukemia cell proliferation. Cancer Res. 2008; 68(10):3733-42. PMC: 2443690. DOI: 10.1158/0008-5472.CAN-07-2509. View

Krivtsov A, Twomey D, Feng Z, Stubbs M, Wang Y, Faber J . Transformation from committed progenitor to leukaemia stem cell initiated by MLL-AF9. Nature. 2006; 442(7104):818-22. DOI: 10.1038/nature04980. View

Kang X, Lu Z, Cui C, Deng M, Fan Y, Dong B . The ITIM-containing receptor LAIR1 is essential for acute myeloid leukaemia development. Nat Cell Biol. 2015; 17(5):665-77. PMC: 4417000. DOI: 10.1038/ncb3158. View

Chan R, Feng G . PTPN11 is the first identified proto-oncogene that encodes a tyrosine phosphatase. Blood. 2006; 109(3):862-7. PMC: 1785139. DOI: 10.1182/blood-2006-07-028829. View

Zheng J, Umikawa M, Zhang S, Huynh H, Silvany R, Chen B . Ex vivo expanded hematopoietic stem cells overcome the MHC barrier in allogeneic transplantation. Cell Stem Cell. 2011; 9(2):119-30. PMC: 3151486. DOI: 10.1016/j.stem.2011.06.003. View

Kitsos C, Sankar U, Illario M, Colomer-Font J, Duncan A, Ribar T . Calmodulin-dependent protein kinase IV regulates hematopoietic stem cell maintenance. J Biol Chem. 2005; 280(39):33101-8. DOI: 10.1074/jbc.M505208200. View

Syken J, GrandPre T, Kanold P, Shatz C . PirB restricts ocular-dominance plasticity in visual cortex. Science. 2006; 313(5794):1795-800. DOI: 10.1126/science.1128232. View

Deng M, Lu Z, Zheng J, Wan X, Chen X, Hirayasu K . A motif in LILRB2 critical for Angptl2 binding and activation. Blood. 2014; 124(6):924-35. PMC: 4126332. DOI: 10.1182/blood-2014-01-549162. View

Wang T, Wei J, Sabatini D, Lander E . Genetic screens in human cells using the CRISPR-Cas9 system. Science. 2013; 343(6166):80-4. PMC: 3972032. DOI: 10.1126/science.1246981. View

10.

Cheng J, Kinjo K, Judelson D, Chang J, Wu W, Schmid I . CREB is a critical regulator of normal hematopoiesis and leukemogenesis. Blood. 2007; 111(3):1182-92. PMC: 2214769. DOI: 10.1182/blood-2007-04-083600. View

11.

Chen X, Zheng J, Zou Y, Song C, Hu X, Zhang C . IGF binding protein 2 is a cell-autonomous factor supporting survival and migration of acute leukemia cells. J Hematol Oncol. 2013; 6(1):72. PMC: 3851819. DOI: 10.1186/1756-8722-6-72. View

12.

Lu Z, Xie J, Wu G, Shen J, Collins R, Chen W . Fasting selectively blocks development of acute lymphoblastic leukemia via leptin-receptor upregulation. Nat Med. 2016; 23(1):79-90. PMC: 6956990. DOI: 10.1038/nm.4252. View

13.

Xie J, Chen X, Zheng J, Li C, Stacy S, Holzenberger M . IGF-IR determines the fates of BCR/ABL leukemia. J Hematol Oncol. 2015; 8:3. PMC: 4320836. DOI: 10.1186/s13045-015-0106-8. View

14.

BLERY M, Kubagawa H, Chen C, Vely F, Cooper M, Vivier E . The paired Ig-like receptor PIR-B is an inhibitory receptor that recruits the protein-tyrosine phosphatase SHP-1. Proc Natl Acad Sci U S A. 1998; 95(5):2446-51. PMC: 19370. DOI: 10.1073/pnas.95.5.2446. View

15.

Takai T, Nakamura A, Endo S . Role of PIR-B in autoimmune glomerulonephritis. J Biomed Biotechnol. 2010; 2011:275302. PMC: 2952822. DOI: 10.1155/2011/275302. View

16.

Somervaille T, Cleary M . Identification and characterization of leukemia stem cells in murine MLL-AF9 acute myeloid leukemia. Cancer Cell. 2006; 10(4):257-68. DOI: 10.1016/j.ccr.2006.08.020. View

17.

Sun P, Enslen H, Myung P, Maurer R . Differential activation of CREB by Ca2+/calmodulin-dependent protein kinases type II and type IV involves phosphorylation of a site that negatively regulates activity. Genes Dev. 1994; 8(21):2527-39. DOI: 10.1101/gad.8.21.2527. View

18.

Lukk M, Kapushesky M, Nikkila J, Parkinson H, Goncalves A, Huber W . A global map of human gene expression. Nat Biotechnol. 2010; 28(4):322-4. PMC: 2974261. DOI: 10.1038/nbt0410-322. View

19.

Uehara T, BLERY M, Kang D, Chen C, Ho L, Gartland G . Inhibition of IgE-mediated mast cell activation by the paired Ig-like receptor PIR-B. J Clin Invest. 2001; 108(7):1041-50. PMC: 200947. DOI: 10.1172/JCI12195. View

20.

Zheng J, Umikawa M, Cui C, Li J, Chen X, Zhang C . Inhibitory receptors bind ANGPTLs and support blood stem cells and leukaemia development. Nature. 2012; 485(7400):656-60. PMC: 3367397. DOI: 10.1038/nature11095. View